• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » The Effect of Age and Pubertal Stage on Mental Health in Gender-Incongruent Youths

The Effect of Age and Pubertal Stage on Mental Health in Gender-Incongruent Youths

May 20, 2021
John Raiss, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
John Raiss, MD. Dr. Raiss has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Sorbara JC et al, Pediatrics 2020;146(4):e20193600

Gender incongruence means that a young person identifies with a gender that’s different from the one they were born with. These youths have an elevated risk of suicide and other psychiatric problems. Gender-affirming medical care (GAMC), such as hormonal therapies, can reduce those risks, but when is it best to start those treatments?

An earlier study found that psychiatric outcomes were better when youths began GAMC before age 12 compared to those who transitioned in adolescence. This newer study builds on this literature by examining the association of both age and pubertal stage at presentation for GAMC on mental health.

The researchers undertook a chart review of 300 patients at a Canadian clinic for transgender youths. They compared outcomes for two groups: those presenting before age 15 (n = 116, median age 14) and those presenting after age 15 (n = 184, median age 16). Most were assigned female at birth (75%), and the majority were Caucasian (72%). The rate of autism (6%) was higher than that of the general population.

Youths who started treatment after age 15 had higher rates of depression (46% vs 30%), self-harm (40% vs 28%), suicide attempts (17% vs 9%), and psychiatric medication use (36% vs 23%). They also recognized their gender incongruence later (median age 9 vs 6) and socially transitioned later (15 vs 13).

Stage of puberty at the time of starting hormones was even more predictive of problems than age. Late pubertal youths (Tanner Stage 4 or 5) were 4–5 times more likely to report depressive or anxiety disorders. The gender assigned at birth was also predictive, with those transitioning from female to male reporting a threefold higher rate of self-harm than those transitioning male to female. Older teens were more likely to be taking psychotropic medications.

The study’s main limitation is its uncontrolled design, which leaves open the possibility that the youths who presented later were already at risk for psychiatric problems. It may be that youths with more secure identities and supportive families are simply more likely to seek these services at a younger age.

CCPR’s Take
This field is complex. We have a lot to learn about such things as possible differences between patients who experience gender dysphoria earlier in life vs at or around puberty. Still, this study brings reassuring data for families who are considering gender-affirming hormones before the onset of puberty. Outcomes are apparently better when treatment is started before secondary sexual characteristics begin to develop.
Child Psychiatry
KEYWORDS adolescents children gamc gdd gender-affirming-medical-care gender-dysphoric-disorder hormone-replacement-therapy hrt mental-health suicidality
John Raiss, MD.

SSRIs vs SNRIs in Pediatric Anxiety Disorders: Which Are More Tolerable?

More from this author
www.thecarlatreport.com
Issue Date: May 20, 2021
SUBSCRIBE NOW
Table Of Contents
Welcome to the 21st Century Cures Act Information Sharing Rules
ECT in Severe Adolescent Mood ­Disorders
The Effect of Age and Pubertal Stage on Mental Health in Gender-Incongruent Youths
Note From the Editor-in-Chief
Approaches to Autism Intervention
Effect Size Matters: The Seismic Shift Toward Naturalistic and Developmental Interventions in Autism
Viloxazine (Qelbree): A Faster Strattera?
Pharmacotherapy for Autism Spectrum Disorder
CME Post-Test - Autism in Children and Adolescents, CCPR, April/May/June 2021
DOWNLOAD NOW
Featured Book
  • CMFB2e_Cover.png

    (PRE-ORDER) Child Medication Fact Book for Psychiatric Practice, Second Edition (2023)

    All the important facts covering child and adolescent psychopharmacology.
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto52138604.jpg
    Child Psychiatry

    Readily Available and Easily Abused Over-the-Counter Medications

    Reviewing four commonly abused substances that are legally available for purchase: Dextromethorphan, antihistamines, pseudoephedrine, and Kratom.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.